信达生物(01801.HK)与驯鹿医疗合研细胞注射液获药监局认定
信达生物(01801.HK)公布,与驯鹿医疗双方合作开发的全人源BCMA嵌合抗原受体自体T细胞注射液(IBI326),已通过国家药品监督管理局药品审评中心公示期,纳入「突破性治疗药物品种」,拟定适应症为复发/难治性多发性骨髓瘤(R/R MM)。
信达生物医学科学与战略肿瘤部副总裁周辉表示,IBI326纳入药品审评中心突破性治疗药物程序,说明该款药物在治疗R/R MM极具潜力,希望该款药物早日上市惠及更多的患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.